Aflibercept ELISA Kit

The Structure of Aflibercept ELISA Kit

Aflibercept ELISA Kit is a highly sensitive and specific assay designed for the quantitative measurement of Aflibercept in biological samples. Aflibercept is a recombinant fusion protein composed of human IgG1 Fc and the extracellular domains of VEGF receptor 1 and 2. The structure of Aflibercept consists of two identical heavy chains and two identical light chains, each containing a variable and constant region. The heavy and light chains are linked by disulfide bonds, forming a Y-shaped structure. The variable regions of the heavy and light chains are responsible for binding to VEGF-A, VEGF-B, and PlGF, while the constant region of the heavy chain is responsible for binding to Fc receptors.

The Aflibercept ELISA Kit utilizes a sandwich enzyme-linked immunosorbent assay (ELISA) format, where a monoclonal antibody specific to Aflibercept is coated onto the surface of a microplate. The sample containing Aflibercept is then added to the plate, allowing for specific binding of Aflibercept to the coated antibody. A second biotinylated monoclonal antibody is then added, which binds to a different epitope on Aflibercept. This is followed by the addition of streptavidin-conjugated horseradish peroxidase (HRP), which binds to the biotinylated antibody. The addition of a substrate solution results in the formation of a colored product, which is directly proportional to the amount of Aflibercept present in the sample. The absorbance of the colored product is then measured, providing a quantitative measurement of Aflibercept concentration in the sample.

Activity of Aflibercept ELISA Kit

The Aflibercept ELISA Kit has been validated for its high sensitivity and specificity in detecting Aflibercept in various biological samples, including serum, plasma, and cell culture supernatant. The lower limit of detection (LOD) of the assay is <0.1 ng/mL, making it highly sensitive for the detection of low levels of Aflibercept. The assay also has a wide dynamic range of 0.2-20 ng/mL, allowing for the accurate measurement of both low and high levels of Aflibercept in samples. The intra-assay and inter-assay precision of the kit has also been demonstrated to be <10% and <12%, respectively, ensuring reproducible and reliable results.

The activity of Aflibercept ELISA Kit has been extensively tested and validated by various research groups and has been shown to accurately measure Aflibercept levels in samples from both preclinical and clinical studies. The kit has also been used in numerous studies to evaluate the pharmacokinetics and pharmacodynamics of Aflibercept, as well as its efficacy in various disease models.

Application of Aflibercept ELISA Kit

Aflibercept is a potent inhibitor of VEGF-A, VEGF-B, and PlGF, making it a promising therapeutic target for various diseases. The Aflibercept ELISA Kit has been widely used in research studies to measure Aflibercept levels in samples from patients with different diseases, including cancer, macular degeneration, and diabetic retinopathy. The accurate measurement of Aflibercept levels in these disease states has provided valuable insights into the role of Aflibercept in disease progression and treatment response.

Furthermore, the Aflibercept ELISA Kit has also been used in preclinical studies to evaluate the pharmacokinetics and pharmacodynamics of Aflibercept, as well as its efficacy in various disease models. This has helped in the development and optimization of Aflibercept as a therapeutic agent for different diseases.

In conclusion, the Aflibercept ELISA Kit is a highly sensitive and specific assay that has been extensively validated for its accuracy and reproducibility in measuring Aflibercept